Work

Abstract CT137: Initial results from a phase 1 study of an A2a receptor antagonist, administered as monotherapy and in combination with anti-PD1 therapy in patients with advanced non-small cell lung cancer

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct137

Authors: Prantesh Jain, Alexander Spira, Seehoon Lee, Byoung Chul Cho, Enriqueta Felip, Andres Aguilar, Sarah Gordon, Sebastian Ochsenreither, Thomas Wehler, Amanda McGillivray, Ariel Chen, Raja Venkatasubramanian, Rajesh Bandekar, Shu Jin, Rosa Martín-Pérez, Aisha Nasreen Hasan, Brian Henick

Institutions: Roswell Park Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Vall d'Hebron Institute of Oncology, Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Thomas Jefferson University, Charité - Universitätsmedizin Berlin, Universitätsklinikum Gießen und Marburg, Johnson & Johnson (United States), Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center

Language: English

Topic: Adenosine and Purinergic Signaling

Subfield: Physiology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822343

Cites:

Cited by:

Related to: 10